首页> 美国卫生研究院文献>other >Hypothalamic orexin’s role in exacerbated cutaneous vasodilation responses to an anxiogenic stimulus in a surgical menopause model
【2h】

Hypothalamic orexin’s role in exacerbated cutaneous vasodilation responses to an anxiogenic stimulus in a surgical menopause model

机译:下丘脑食欲肽在更年期手术模型中对血管生成刺激的加剧的皮肤血管舒张反应中的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Distressing symptoms such as hot flashes and sleep disturbances affect over 70% of women approaching menopause for an average of 4–7 years, and recent large cohort studies have shown that anxiety and stress are strongly associated with more severe and persistent hot flashes and can induce hot flashes. Although high estrogen doses alleviate symptoms, extended use increases health risks, and current non-hormonal therapies are marginally better than placebo. The lack of effective non-hormonal treatments is largely due to the limited understanding of the mechanisms that underlie menopausal symptoms. One mechanistic pathway that has not been explored is the wake-promoting orexin neuropeptide system. Orexin is exclusively synthesized in the estrogen receptor rich perifornical hypothalamic region, and has an emerging role in anxiety and thermoregulation. In female rodents, estrogens tonically inhibit expression of orexin, and estrogen replacement normalizes severely elevated central orexin levels in postmenopausal women. Using an ovariectomy menopause model, we demonstrated that an anxiogenic compound elicited exacerbated hot flash-associated increases in tail skin temperature (TST, that is blocked with estrogen), and cellular responses in orexin neurons and efferent targets. Furthermore, systemic administration of centrally active, selective orexin 1 or 2 and dual receptor antagonists attenuated or blocked TST responses, respectively. This included the reformulated Suvorexant, which was recently FDA-approved for treating insomnia. Collectively, our data support the hypothesis that dramatic loss of estrogen tone during menopausal states leads to a hyperactive orexin system that contributes to symptoms such as anxiety, insomnia, and more severe hot flashes. Additionally, orexin receptor antagonists may represent a novel non-hormonal therapy for treating menopausal symptoms, with minimal side effects.
机译:潮热和睡眠障碍等令人痛苦的症状影响着超过70%的女性更年期平均持续4-7年,而最近的大型队列研究表明,焦虑和压力与更严重和持续的潮热密切相关,并且可以诱发潮热。尽管高剂量的雌激素可以缓解症状,但长期使用会增加健康风险,目前的非激素疗法比安慰剂略好。缺乏有效的非激素治疗很大程度上是由于对更年期症状的潜在机制了解有限。尚未探索的一种机制途径是促唤醒食欲素神经肽系统。食欲素是在富含雌激素受体的下丘脑周围区域专门合成的,在焦虑和温度调节中起着新的作用。在雌性啮齿动物中,雌激素可以抑制食欲素的表达,而雌激素替代可使绝经后妇女的食欲素中枢严重升高。使用卵巢切除术更年期模型,我们证明了,一种焦虑生成的化合物引发了尾部皮肤温度(TST,被雌激素阻断),以及食欲肽神经元和射出靶细胞反应的加剧的热潮红相关升高。此外,中枢活性,选择性orexin 1或2和双重受体拮抗剂的全身给药分别减弱或阻断了TST反应。这包括重新配制的Suvorexant,最近已获得FDA批准用于治疗失眠症。总的来说,我们的数据支持这样的假说,即在绝经期期间雌激素的急剧丧失会导致活动过度的食欲素系统,该系统导致焦虑,失眠和更严重的潮热等症状。另外,食欲素受体拮抗剂可以代表一种用于治疗更年期症状,副作用最小的新型非激素疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号